TITLE:
Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

CONDITION:
Breast Neoplasms

INTERVENTION:
Letrozole / Temsirolimus (CCI-779)

SUMMARY:

      To evaluate the preliminary activity and pharmacokinetics of 2 separate doses and schedules
      of orally administered Temsirolimus (CCI-779) given in combination with daily letrozole,
      compared to letrozole alone, in the treatment of locally advanced or metastatic breast
      cancer in postmenopausal women. All patients must be appropriate to receive endocrine
      therapy as treatment for advanced disease.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Postmenopausal women with histologically confirmed, measurable locally advanced
             disease or metastatic breast.

          -  Must be appropriate to receive endocrine therapy as treatment for advanced disease
             (chemotherapy; prior adjuvant therapy with antiestrogens other than aromatase
             inhibitors; prior adjuvant or first-line metastatic therapy with tamoxifen or
             trastuzumab, are permitted).

          -  Women may either present with de novo advanced or metastatic cancer, or have had
             tumor progression while receiving adjuvant tamoxifen or at any time after completing
             adjuvant tamoxifen, or have had tumor progression while receiving first-line
             metastatic therapy with tamoxifen.

        Exclusion Criteria:

          -  Patients having known central nervous system (CNS) metastases.

          -  Prior therapy with Temsirolimus (CCI-779) or aromatase inhibitors.

          -  Tamoxifen, or other hormonal therapy, in the metastatic or adjuvant setting within 1
             week prior to day 1 of treatment on study.
      
